Imidazole derivatives, topical antifungals
ATC code: G01AF02 (Clotrimazole)
Brand names
Clotrimazol Cinfa, Canesten, Canespie, Mycelex
Topical antifungal of the imidazole class. Inhibits fungal lanosterol 14-alpha-demethylase (CYP51), blocking ergosterol synthesis – a key fungal membrane component. Active against Candida albicans, dermatophytes (Trichophyton, Microsporum, Epidermophyton), Malassezia, Cryptococcus. Topical bioavailability is minimal (under 0.5%), no systemic effects reported.
First line
First-line for acute vulvovaginal candidiasis per CDC 2021 and Spanish SEGO 2023. Regimen: 200 mg vaginal tablet at bedtime for 3 days or 500 mg single dose, plus 1-2% cream to external genitalia twice daily for 1-2 weeks. Efficacy 80-90%. For recurrent candidiasis (>=4 episodes per year), add oral fluconazole 150 mg weekly for 6 months.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Clotrimazole is an imidazole antifungal. It is prescribed for cutaneous and mucosal candidiasis and other superficial mycoses (AEMPS Ficha Técnica). In alt detox circles, clotrimazole is occasionally promoted for systemic fungal cleansing in intestinal candidiasis without confirmed diagnosis. Systemic intestinal candidiasis is not recognized as an independent diagnosis in immunocompetent people in international medicine; dysbiosis as an interchangeable concept lacks agreed diagnostic criteria. In people without confirmed invasive candidiasis, no clinical studies of systemic clotrimazole prophylactic use exist, and the drug's oral bioavailability is low – it acts mainly topically. If clotrimazole was prescribed orally for systemic cleansing, consider seeking a second opinion.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
FDA category B. First-line for candidiasis in T2-T3. In T1, Spanish SEGO 2023 prefers to avoid vaginal forms without clear need; use external cream.
Systemic absorption is minimal. Safe during lactation, including treatment of nipple candidiasis.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Clotrimazole is evaluated for the following indications with varying evidence strength: Vulvovaginal candidiasis (evidence tier A), Body detoxification and cleansing (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Clotrimazole (≥ 1 in 100): Local burning and itching at start, Skin irritation, Contact dermatitis (rare). See the Safety section for uncommon and serious reactions.
FDA category B. FDA category B. First-line for candidiasis in T2-T3. In T1, Spanish SEGO 2023 prefers to avoid vaginal forms without clear need; use external cream.
Systemic absorption is minimal. Safe during lactation, including treatment of nipple candidiasis.
Clotrimazole is contraindicated in: Clotrimazole or imidazole hypersensitivity; First trimester pregnancy (vaginal forms – relative). Full list in the Safety section.